Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that mediates the adaptation of tumor cells and tissues to the hypoxic microenvironment, has attracted considerable interest as a potential therapeutic target. Tirapazamine (TPZ), a well-characterized bioreductive anticancer agent, is currently in Phase II and III clinical trials. A major aspect of the anticancer activity of TPZ is its identity as a tumor-specific topoisomerase IIα inhibitor. In the study, for the first time, we found that TPZ acts in a novel manner to inhibit HIF-1α accumulation driven by hypoxia or growth factors in human cancer cells and in HepG2 cell-derived tumors in athymic nude mice. We investigated the mechanism of TPZ on HIF-1α in HeLa human cervical cancer cells by western blot analysis, reverse transcription-PCR assay, luciferase reporter assay and small interfering RNA (siRNA) assay. Mechanistic studies demonstrated that neither HIF-1α mRNA levels nor HIF-1α protein degradation are affected by TPZ. However, TPZ was found to be involved in HIF-1α translational regulation. Further studies revealed that the inhibitory effect of TPZ on HIF-1α protein synthesis is dependent on the phosphorylation of translation initiation factor 2α (eIF2α) rather than the mTOR complex 1/eukaryotic initiation factor 4E-binding protein-1 (mTORC1/4E-BP1) pathway. Immunofluorescence analysis of tumor sections provide the in vivo evidences to support our hypothesis. Additionally, siRNA specifically targeting topoisomerase IIα did not reverse the ability of TPZ to inhibit HIF-1α expression, suggesting that the HIF-1α inhibitory activity of TPZ is independent of its topoisomerase IIα inhibition. In conclusion, our findings suggest that TPZ is a potent regulator of HIF-1α and provide new insight into the potential molecular mechanism whereby TPZ serves to reduce HIF-1α expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulating evidence now supports the conclusion that inhibition of HIF signaling by these agents occurs in a topoisomerase I- or II-dependent manner [309,310] but is largely independent of their canonical cytotoxic effects [311].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [309]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Hypoxia-Inducible Factor-1 (HIF-1)
Ke, Q., & Costa, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027029 · Cited by 1,646
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The sense strands of siRNAs against 4E-BP1, TSC2, topoisomerase IIa, and eIF2a were as follows: 4E-BP1: GGUACCAGG AUCAUCUAUGTT [40]; TSC2: CAAUGAGUCACAGUCCUUU GA (a) and AAAGU UCACCUACUGCUGGCA (b) [41]; topoisomerase IIa: GGUAUUCCUGUUGUUGAAC [42]; eIF2a: GGCUUGUUAUGGUUAUGAA(a), CCUCGGUAUGUAAUGACUA(b) and GAGAGGCUUGAAA…”
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
Lin, J. H., Li, H., Yasumura, D., Cohen, H. R., Zhang, C., Panning, B., Shokat, K. M., LaVail, M. M., & Walter, P. (2007) · Science · doi:10.1126/science.1146361 · Cited by 1,370
A trip to the ER: coping with stress
Rutkowski, D. T., & Kaufman, R. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2003.11.001 · Cited by 1,355
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894 · cited 1×
“hypoxia [2,3].”
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 2×
“HIF-1a accumulation induced by the prolyl hydroxylase inhibitor cobalt chloride (CoCl2), a wellcharacterized hypoxia mimetic agent [3], was unaffected by normoxia and treatment with TPZ (Fig.”
Background(2001) · PubMed · Cited by 557
A transgenic mouse model for monitoring endoplasmic reticulum stress
Iwawaki, T., Akai, R., Kohno, K., & Miura, M. (2004) · Nature Medicine · doi:10.1038/nm970 · Cited by 471
SEGLEN, P. O., GRINDE, B., & SOLHEIM, A. E. (1979) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1979.tb12956.x · Cited by 469
The hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334
Jiang, H.-Y., & Wek, R. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413660200 · Cited by 312
Safran, M., Kim, W. Y., O'Connell, F., Flippin, L., Günzler, V., Horner, J. W., DePinho, R. A., & Kaelin, W. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509459103 · Cited by 305 · cited 1×
“Importantly, the ODD region of HIF-1a is sufficient for oxygendependent degradation [25].”
Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms
Dunlop, E. A., & Tee, A. R. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.012 · Cited by 258
Roybal, C. N., Yang, S., Sun, C.-W., Hurtado, D., Vander Jagt, D. L., Townes, T. M., & Abcouwer, S. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312948200 · Cited by 230
Lowell, B. B., Ruderman, N. B., & Goodman, M. N. (1986) · Biochemical Journal · doi:10.1042/bj2340237 · Cited by 221
Aharonowiz, M., Einstein, O., Fainstein, N., Lassmann, H., Reubinoff, B., & Ben-Hur, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003145 · Cited by 214
Vega, F., Medeiros, L. J., Leventaki, V., Atwell, C., Cho-Vega, J. H., Tian, L., Claret, F.-X., & Rassidakis, G. Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3018 · Cited by 196
García-Maceira, P., & Mateo, J. (2009) · Oncogene · doi:10.1038/onc.2008.398 · Cited by 185
Fu, B., Xue, J., Li, Z., Shi, X., Jiang, B.-H., & Fang, J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0526 · Cited by 181
Kim, K. M., Pae, H.-O., Zheng, M., Park, R., Kim, Y.-M., & Chung, H.-T. (2007) · Circulation Research · doi:10.1161/circresaha.107.154781 · Cited by 177
Sun, H.-L., Liu, Y.-N., Huang, Y.-T., Pan, S.-L., Huang, D.-Y., Guh, J.-H., Lee, F.-Y., Kuo, S.-C., & Teng, C.-M. (2007) · Oncogene · doi:10.1038/sj.onc.1210169 · Cited by 171
Endoplasmic reticulum stress in disease: mechanisms and therapeutic opportunities
Hosoi, T., & Ozawa, K. (2010) · Clinical Science · doi:10.1042/cs20080680 · Cited by 164
Li, S. H., Shin, D. H., Chun, Y.-S., Lee, M. K., Kim, M.-S., & Park, J.-W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0074 · Cited by 160
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso, Y., Tomida, A., Lei, S., Ōmura, S., & TSURUO, T. (2000) · PubMed · Cited by 141
Endoplasmic Reticulum Stress and the Unfolded Protein Response
Kapoor, A., & Sanyal, A. J. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.004 · Cited by 119
Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters, K. B., & Brown, J. M. (2002) · PubMed · Cited by 117
HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Semenza, G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649402 · Cited by 116 · cited 2×
“We observed that etoposide and adriamycin had no effect on the expression of HIF-1a, which is consistent with recent studies [13,36].”
Regulation of CHK2 by DNA-dependent Protein Kinase
Li, J., & Stern, D. F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412445200 · Cited by 102
Craighead, P. S., Pearcey, R. G., & Stuart, G. C. E. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00720-3 · Cited by 82
Duyndam, M. C. A., van Berkel, M. P. A., Dorsman, J. C., Rockx, D., Pinedo, H. M., & Boven, E. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.04.003 · Cited by 80
Delahoussaye, Y. M., Evans, J., & Brown, J. M. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00784-5 · Cited by 66
Inhibition of Hypoxia-Inducible Factor-1α (HIF-1α) Protein Synthesis by DNA Damage Inducing Agents
Lou, J. J. W., Chua, Y. L., Chew, E. H., Gao, J., Bushell, M., & Hagen, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010522 · Cited by 57
Control of HIF-1α Expression by eIF2α Phosphorylation–Mediated Translational Repression
Zhu, K., Chan, W., Heymach, J., Wilkinson, M., & McConkey, D. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4103 · Cited by 55
Creighton-Gutteridge, M., Cardellina, J. H., Stephen, A. G., Rapisarda, A., Uranchimeg, B., Hite, K., Denny, W. A., Shoemaker, R. H., & Melillo, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2301 · Cited by 51
Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway
Manolescu, B. N., Oprea, E., Buşu, C., & Cercasov, C. (2009) · Biochimie · doi:10.1016/j.biochi.2009.08.005 · Cited by 50
Magagnin, M. G., van den Beucken, T., Sergeant, K., Lambin, P., Koritzinsky, M., Devreese, B., & Wouters, B. G. (2008) · PROTEOMICS · doi:10.1002/pmic.200700551 · Cited by 44
Lau, C. K., Yang, Z. F., Lam, C. T., Tam, K. H., Poon, R. T. P., & Fan, S. T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.015 · Cited by 43
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer
Maluf, F. C., Leiser, A., Aghajanian, C. A., Sabbatini, P. J., Pezzulli, S., Chi, D. S., Wolf, J. K., Levenback, C., Loh, E. Y., & Spriggs, D. R. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00454.x · Cited by 40
Dai, M., Miao, Z., Ren, X., Tong, L., Yang, N., Li, T., Lin, L., Shen, Y., & Ding, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00822.x · Cited by 16
Reck, M., von Pawel, J., Nimmermann, C., Groth, G., & Gatzemeier, U. (2004) · Pneumologie · doi:10.1055/s-2004-830056 · Cited by 11
Reck, M., von Pawel, J., Nimmermann, C., Groth, G., & Gatzemeier, U. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)92171-4 · Cited by 4
Research works printed but not linked: 1
- YM Delahoussaye, 2001, Metabolism of tirapazamine by multiple reductases in the nucleus., Biochem Pharmacol, 62, 1201
Cited by
Singhal, R., & Shah, Y. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011188 · Cited by 376
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
Mi, C., Ma, J., Wang, K. S., Zuo, H. X., Wang, Z., Li, M. Y., Piao, L. X., Xu, G. H., Li, X., Quan, Z. S., et al. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.03.033 · Cited by 122
Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions
Cheng, G., Sa, W., Cao, C., Guo, L., Hao, H., Liu, Z., Wang, X., & Yuan, Z. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00064 · Cited by 118
Hutt, D. M., Roth, D. M., Vignaud, H., Cullin, C., & Bouchecareilh, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106224 · Cited by 109
Metadata
- Authors
- Zhang, J., Cao, J., Weng, Q., Wu, R., Yan, Y., Jing, H., Zhu, H., He, Q., & Yang, B.
- Affiliations
- Zhejiang University (CN)
- Corresponding author
- He, Qiaojun
- Yang, Bo
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-11-09
- Volume
- 5
- Issue
- 11
- Pages
- e13910
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2976688
- OpenAlex
- W2062776433
- Cited by
- 56
- References
- 48
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 7 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 6 · 2017: 5 · 2016: 5 · 2015: 4 · 2014: 7 · 2013: 7 · 2012: 3
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Chinese Academy of Sciences
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Zhejiang Province (Z2090053)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tirapazamine, hypoxia-inducible factor-1α, eIF2α phosphorylation, translational regulation, TOP2A, tumor hypoxia, HeLa cervical cancer cells
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Tirapazamine, Animals, Antigens, Neoplasm, Antineoplastic Agents, DNA Topoisomerases, Type II, DNA-Binding Proteins, Female, HeLa Cells, Humans, Liver Neoplasms, Experimental, Mice, Inbred BALB C, Mice, Nude, Phosphoproteins, Phosphorylation, Proteins, Transplantation, Heterologous, Triazines, Blotting, Western, Signal Transduction, Cell Hypoxia, Eukaryotic Initiation Factor-2, Cell Cycle Proteins, Reverse Transcriptase Polymerase Chain Reaction, RNA Interference, Cell Line, Tumor, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Hep G2 Cells, HEK293 Cells, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.